Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
As per available reports about 1 Relevant Journal, 12 Conferences, 17 National Symposiums are presently dedicated exclusively to microchip technology and about 7 articles are being published on microchip technology.
The futuristic idea that microchips could be implanted under a patient's skin to control the release of drugs has taken another step forward. An experimental, implanted drug-delivery microchip that releases medication on command from an external wireless control could one day free patients from daily injections and improves treatment compliance. The first study of this approach in people shows that microchips implanted under the skin deliver regular doses of a drug to fight osteoporosis, the bone-weakening condition common in the elderly. Ultimately, this technology may help treat a variety of diseases, including multiple sclerosis and cancer.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
The prospect of medical implants capable of delivering drugs directly to the patient’s blood stream or tissue has been an important subject for research. Recently, a microchip was implanted in 8 women, with the sole role of delivering an osteoporosis treating drug. New advancements, new product launches, along with increased awareness and early detection of the disease are expected to influence the market growth in the foreseeable future.
The prospect of medical implants capable of delivering drugs directly to the patient’s blood stream or tissue has been an important subject for research. Recently, a microchip was implanted in 8 women, with the sole role of delivering an osteoporosis treating drug. The human trial is the culmination of 15 years’ worth of development work by MIT scientists.
Just 5 cm long and 3 cm wide, the microchip was implanted in less than 30 minutes, as the patients were under local anaesthesia. The device has 20 tiny reservoirs, each holding 600-nanoliters of drug solution, at the bottom of which a thin layer of platinum or titanium was coated. When the payload had to be released, an electrical current passed through the reservoir, melting the bottom layer. This action could be programmed or triggered manually via a wireless command. Concerning treatment reports, the patients who had their drugs delivered via the implant fared just as well as those who had it injected. Due to its bidirectional nature, this allowed the researchers to both notice whether the device functioned properly or not, and monitor its performance.
The demand for an automated drug delivery solution has been at large for a while now, as it’s considered it can address a number of issues which inherently come along with traditional medical treatment. One big problem that interferes with a successful treatment is the patient himself. It’s imperative for a patient to follow his prescribed drug treatment clockwise for the whole duration of it, otherwise, most often; the whole treatment will render poor results.
The global market for circulating tumour cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.
International symposium and workshops:
Relevant Society and Associations:
This page will be updated regularly.
This page was last updated on October 21, 2020